Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Georgia's Online Cancer Information Center

Find A Clinical Trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Status
Active
Cancer Type
Lung Cancer
Trial Phase
Phase III
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06767514
Protocol IDs
SMT112-3007 (primary)
NCI-2025-01500
Study Sponsor
Summit Therapeutics

Summary

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with
high PD-L1. Evaluating overall survival and progression free survival.

Eligibility

  1. Age = 18 years old at the time of enrollment
  2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
  3. Expected life expectancy = 3 months
  4. Metastatic (Stage IV) NSCLC
  5. Histologically or cytologically confirmed squamous or non-squamous NSCLC
  6. Tumor demonstrates high PD-L1 expression ( TPS>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities.
  7. At least one measurable noncerebral lesion according to RECIST 1.1
  8. No prior systemic treatment for metastatic NSCLC.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.